(Q48889821)

16 February 2018

title

EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. (English)

1 reference

16 February 2018

author name string

Dongdong Luo

1

1 reference

16 February 2018

Xin Ye

2

1 reference

16 February 2018

Zheng Hu

3

1 reference

16 February 2018

Kaiwen Peng

4

1 reference

16 February 2018

Ye Song

5

1 reference

16 February 2018

Xiaolu Yin

6

1 reference

16 February 2018

Guanshan Zhu

7

1 reference

16 February 2018

Qunsheng Ji

8

1 reference

16 February 2018

Yuping Peng

9

1 reference

16 February 2018

publication date

7 November 2013

1 reference

16 February 2018

published in

Tumor Biology

1 reference

16 February 2018

volume

35

1 reference

16 February 2018

issue

3

1 reference

16 February 2018

page(s)

2437-2444

1 reference

16 February 2018

https://scigraph.springernature.com/pub.10.1007/s13277-013-1323-9

exact match

0 references

cites work

Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Frequent EGFR mutations in brain metastases of lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

KRAS mutation status in primary nonsmall cell lung cancer and matched metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1323-9

Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis

21 January 2018

1 reference

12 December 2020

Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

1 reference

12 December 2020

Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response

1 reference

12 December 2020

Brain metastases from undiagnosed systemic neoplasms

1 reference

12 December 2020

10.1007/S13277-013-1323-9

Identifiers

DOI

1 reference

16 February 2018

PubMed ID

24197981

1 reference

16 February 2018